The active pharmaceutical ingredient (S)-3-Amino-3-phenylpropanoic acid Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied as the free amino acid, not as a hydrochloride or other salt. The molecular formula is C₉H₁₁NO₂, with a formula weight of 165.19 g/mol. The molecule contains a single asymmetric center at the beta carbon, placing the amino group two bonds removed from the carboxylate and classifying the compound as a chiral beta-amino acid. This feature separates the product from alpha-amino acids such as L-phenylalanine and from the corresponding racemic 3-amino-3-phenylpropanoic acid. Pharmaceutical-grade material is released under ICH Q7 good manufacturing practice with a certificate of analysis that includes appearance, infrared identification, assay by HPLC, enantiomeric purity by chiral HPLC, water content by Karl Fischer titration, residue on ignition, residual solvents, and elemental impurities. Because a harmonized pharmacopoeial monograph for this exact chiral free acid may not exist, release specifications are usually developed from ICH Q6A decision trees and validated supplier methods. The product is used in drug product development for immediate-release tablets, capsules, granules, and injectable dosage forms where the free acid can be dissolved, suspended, or blended without conversion to a salt unless the formulation specifically requires pH adjustment.

The free acid should be distinguished from technical-grade or research-grade material. Pharma grade designation means the batch is supported by a complete certificate of analysis, stability data under controlled storage, and a change-control system; it does not indicate a specific particle-size distribution or polymorphic form unless these attributes are stated in the supplier specification. In procurement records this product is commonly listed under its systematic name and the descriptor “pharma grade API, oral and injectable,” rather than a single harmonized code. Each batch is identified by a supplier lot number that links the certificate of analysis to manufacturing records and to the stereochemical release data.

How does enantiomeric purity alter formulation development for tablets and capsules?

Enantiomeric purity is a release-critical quality attribute for this product because the single stereocenter separates the (S)-configuration from the (R)-enantiomer. A typical pharma-grade release criterion is ≥ 98.0% enantiomeric excess by normalized chiral HPLC peak area, with total unspecified impurities not exceeding 0.5%. The racemic 3-amino-3-phenylpropanoic acid is not equivalent to the single enantiomer; it can show different solid-state behavior, dissolution, and thermodynamic stability if the two enantiomers form a racemic compound or a conglomerate. Tablet and capsule batches containing racemic material therefore cannot be substituted for the (S)-enantiomer without repeating dissolution, stability, and possibly bioequivalence evaluation. The (R)-enantiomer, if present above the limit, is controlled by a chiral method capable of baseline resolution with a minimum resolution of 1.5 between the two peaks. For formulation development, enantiomeric stability should also be checked under stress; high-heat and high-humidity conditions used in granulation or drying can reveal whether racemization is thermally or pH-dependent. Where racemization is observed, the processing window must be narrowed to maintain the chiral purity established in the drug product specification.

For tablet, capsule, and granule manufacture, the crystalline free acid is usually delumped or milled before weighing. The milled material is characterized according to USP <616> bulk density and tapped density, USP <1174> flowability, and laser-diffraction particle-size distribution. Direct compression is evaluated only after the bulk and tapped density have been measured; a Hausner ratio above 1.35 generally indicates marginal flow and may require dry granulation. Dry granulation with a roller compactor is preferred when water exposure must be minimized, but the ribbons must be milled under controlled screen size to avoid producing excessive fines that reduce capsule fill weight consistency. Wet granulation in a high-shear mixer can be used when the API is stable to the granulating fluid, but the primary amine restricts excipient selection. Reducing sugars and aldehydes should be avoided or justified by binary forced-degradation data because the amino group can form imine adducts. If lactose monohydrate is used, granulation time, water content, and drying temperature must be controlled to limit Maillard-related degradation. Pre-drying of the API at 40–50 °C under vacuum may be applied when water content exceeds 0.5% w/w, but drying must be validated to avoid crystallographic changes or agglomeration.

On production-scale rotary tablet presses, the free acid may exhibit punch filming or sticking if the residual moisture is high or if the compression force is not matched to the formulation. A compaction simulator or instrumented rotary press is more informative than a single-station press because dwell time and precompression force influence the compact’s hardness and friability. Capsule filling requires control of powder flow and bulk density after blending; segregation tendency is assessed by sampling from the hopper and the final package. For granules, the particle-size distribution after milling is monitored because an oversized fraction can cause content uniformity drift, while an undersized fraction can reduce flow and increase dust. The processing limits should be established for each supplier lot, because particle-size distribution and moisture content are not intrinsic properties of this specific beta-amino acid but depend on recrystallization and milling conditions.

Granule processing requires the binder to be selected carefully because the free amine can interact with acidic modifiers or polymers that form ionic complexes. The granulation endpoint is monitored by impeller power and mass temperature; an overheated wet mass may cause agglomeration and increase the fraction of oversized granules after drying. Dried granules are milled through a screen and blended with disintegrant and lubricant; the final blend is sampled for content uniformity and for particle-size distribution to verify that the active substance is not preferentially located in the fines.

When terminal sterilization and injectable formulation place stress on the free acid

Injectable applications impose additional controls that oral solid dosage forms do not require. The free amino acid is zwitterionic, and its aqueous solubility is pH-dependent; dissolution may require dilute hydrochloric acid or sodium hydroxide to form a soluble salt in situ. The final solution pH is typically adjusted to 3.0–8.5 unless a narrower range is justified by stability. For terminal sterilization, the solution is evaluated in an autoclave under conditions selected according to the container volume and heat transfer; however, published data for the hydrolytic stability of this specific beta-amino acid under all terminal sterilization cycles are limited, so development batches must be tested for assay, enantiomeric purity, and pH shift after the cycle. Sterile filtration through a low-binding membrane is the preferred alternative when thermal stability is insufficient, but filter compatibility must be confirmed because the primary amine can interact with certain membrane materials and reduce yield or compromise integrity. Injectable-grade material is released with a bacterial endotoxin limit of 0.25 EU/mg or a lower limit derived from the maximum intended dose. The resulting solution must comply with USP <1> Injections, USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, and USP <785> osmolality where applicable.

For parenteral manufacturing, the API is dissolved in a dedicated stainless-steel vessel that has been cleaned to remove reducing residues and endotoxin. The solution is blanketed with filtered nitrogen if oxygen-sensitive; the primary amine may undergo oxidative side reactions under prolonged air exposure, so dissolved oxygen limits may be required. The final filling line uses isolator or restricted access barrier technology when terminal sterilization is not used. Batch-to-batch variance in soluble salt content, residual moisture, and particle morphology should be recorded as part of the vendor qualification, because injectable solution clarity is more sensitive to insoluble particulate contamination than oral granule processing.

Residual solvent, elemental impurity, and genotoxic control during release

Residual solvent and elemental impurity data are not interchangeable between oral and injectable grades, because the injectable route can impose lower limits derived from the permitted daily exposure and the maximum daily dose. For residual solvents, the material is normally controlled to ICH Q3C Class 3 solvents within the concentration limit of 0.5% w/w; Class 1 and Class 2 solvents are excluded unless justified and below the option 1 limit. Elemental impurities are determined after closed-vessel microwave digestion and analyzed by inductively coupled plasma mass spectrometry according to USP <232> and USP <233>, with limits established from ICH Q3D. For potential mutagenic impurities, the control strategy follows ICH M7; any process-related impurity containing an alerting structure is controlled at or below the threshold of toxicological concern of 1.5 µg/day unless a compound-specific limit is derived. Storage instructions for the pharma-grade free acid typically require a tight, light-resistant container at or below 25 °C, with desiccant protection when the container is opened.

Compared with L-phenylalanine, the (S)-3-amino-3-phenylpropanoic acid free acid has the amino group located on the beta carbon, which changes the distance between the amino and carboxylate functions and alters acid dissociation behavior as well as resistance to peptidase-mediated cleavage. Compared with the hydrochloride salt of the same enantiomer, the free acid is less hygroscopic and avoids the counterion contribution to osmolality and tonicity, but it generally requires pH adjustment for aqueous injectable solubility. Compared with the racemic free acid, the single (S)-enantiomer is the appropriate choice when the pharmacological target is stereospecific; the racemate should be reserved for non-chiral synthetic steps or for development work where stereochemical evaluation is not relevant. The pharma grade API also differs from technical-grade material because it is released against a complete GMP certificate of analysis, with lot-to-lot traceability and documented retest dating.

Because the free acid contains both a primary amine and a carboxylate, it should not be blended with strongly reducing excipients, aldehydes, or strong oxidizing agents without compatibility data. For oral and injectable formula development, the processing window is controlled by the combined constraints of enantiomeric purity, water content, particle-size distribution, and endotoxin burden. Open storage at relative humidity above 60% should be avoided unless stability data support it. The product is not a lyophilized sterile powder unless the supplier explicitly labels it as such and provides the corresponding sterility certificate.